Mayo Clinic | Strategic Alliance Partners

MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.

Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.

Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.

Three new articles from The Lancet Hematology published today examine how clinicians and researchers can better identify, track and measure the effects of blood cancer treatments on patients during treatment and over the long term.

Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

Rafael Fonseca, MD, discusses why CAR T-cell therapy could be considered at first relapse in multiple myeloma.

Rafael Fonseca, MD, discusses how FISH, NGS, and minimal residual disease testing guide risk stratification and treatment in multiple myeloma.

In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Colorectal cancer is not the only gastrointestinal cancer that doctors are diagnosing in patients below the age of 50.

Continuing maintenance therapy with lenalidomide beyond 2 years after initial treatment did not improve overall survival in standard-risk myeloma.

A Mayo Clinic study found that a new immunotherapy helped patients with aggressive bladder cancer keep their bladder instead of having it removed.

Dr Bekaii-Saab discusses the current state of the metastatic colorectal cancer treatment landscape and potential future research directions.

Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.

GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.

Tanios S. Bekaii-Saab, MD, discusses FIGHT-302 data showing frontline pemigatinib significantly improves PFS in FGFR2-positive cholangiocarcinoma.

Tanios S. Bekaii-Saab, MD, discusses the clinical significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive CCA.

Sikander Ailawadhi, MD, discusses the ongoing evaluation of cemsidomide in relapsed/refractory multiple myeloma.

Mayo Clinic shows thymus preps CD8 T cells and uncovers molecular structures of PKCβ, a protein linked to cancer, refining immunotherapy.

Mayo Clinic scientists have revealed the molecular structures of PKCβ, a key protein linked to cancer and neurological diseases.

Mayo Clinic researchers are advancing brain tumor care through molecular profiling, improved diagnostics for younger patients, new drug delivery methods, and emerging immunotherapies.

Daniel H. Ahn, DO, discusses research surrounding the combination of atebimetinib and modified gemcitabine and nab-paclitaxel (Abraxane) in pancreatic cancer.

Mark D. Tyson, II, MD, MPH, discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC.

Mark D. Tyson, II, MD, MPH, discusses how TARA-002 could fit into the treatment landscape of BCG-naive NMIBC.

Mark D. Tyson, II, MD, MPH, discusses efficacy data with TARA-002 in patients with BCG-naive high-grade non–muscle-invasive bladder cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses how the REDMOD AI model could help identify prediagnostic pancreatic cancer on CT scans missed by radiologists.

Mayo Clinic researchers are advancing brain tumor care through molecular profiling, improved diagnostics for younger patients, new drug delivery methods, and emerging immunotherapies.

Mayo Clinic researchers developed a blood-based method that may help detect germ cell tumors.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors.